← Back to Patent Explorer
US4052505A Expired / Lapsed US ⏱️ 0.0 years remaining

Ocular therapeutic system manufactured from copolymer

Assignee: Alza Corp
•
Filing: 1976-07-15
•
Granted: 1977-10-04
•
Expires: 1996-07-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Drug-delivery device for releasing a drug at a continuous and controlled rate for a prolonged period of time is comprised of a shaped body of polymeric material containing a pharmaceutically acceptable drug and permeable to passage of the drug by diffusion. The polymeric material is an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight and a melt index of about 0.1 to 1000 grams per 10 minutes.

Inventors

  • 👤 Takeru Higuchi
  • 👤 Anwar Hussain

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 04:22
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61K9/0002; A61K9/0004; A61K9/0012; A61K9/0034; A61K9/0039; A61K9/0048; A61K9/0051

Claims Analysis

Total Claims: 24
Claim 1
Independent Claim 117 words
An ocular therapeutic system for the controlled release of drug comprising a flexible body formed of a polymeric material permeable to the passage of drug by diffusion and containing a drug capable of diffusing through the material at a therapeutically effective rate, the body shaped, sized and adapted for comfortable insertion and retention in the cul-de-sac of the conjuctiva between the sclera of the eyeball and the lid to be held in place against the eyeball by the pressure of the lid, and wherein said polymeric material comprises an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight, and a melt index of about 0.1 to 1000 grams per ten minutes.
Claim 2
Dependent Claim 117 words
An ocular therapeutic system for the controlled release of drug comprising a flexible body formed of a polymeric material permeable to the passage of drug by diffusion and containing a drug capable of diffusing through the material at a therapeutically effective rate, the body shaped, sized and adapted for comfortable insertion and retention in the cul-de-sac of the conjuctiva between the sclera of the eyeball and the lid to be held in place against the eyeball by the pressure of the lid, and wherein said polymeric material comprises an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight, and a melt index of about 0.1 to 1000 grams per ten minutes.
Claim 3
Dependent Claim 14 words
The ocular system according to claim 1 wherein the drug is an ophthalmic drug.
Claim 4
Dependent Claim 12 words
The ocular system according to claim 1 wherein the drug is pilocarpine.
Claim 5
Dependent Claim 117 words
An ocular therapeutic system for the controlled release of drug comprising a flexible body formed of a polymeric material permeable to the passage of drug by diffusion and surrounding a drug capable of diffusing through the material at a therapeutically effective rate, the body shaped, sized and adapted for comfortable insertion and retention in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lid, to be held in place against the eyeball by the pressure of the lid, and wherein said polymeric material comprises an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight, and a melt index of about 0.1 to 1000 grams per ten minutes.
Claim 6
Dependent Claim 117 words
An ocular therapeutic system for the controlled release of drug comprising a flexible body formed of a polymeric material permeable to the passage of drug by diffusion and surrounding a drug capable of diffusing through the material at a therapeutically effective rate, the body shaped, sized and adapted for comfortable insertion and retention in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lid, to be held in place against the eyeball by the pressure of the lid, and wherein said polymeric material comprises an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight, and a melt index of about 0.1 to 1000 grams per ten minutes.
Claim 7
Dependent Claim 17 words
The ocular system according to claim 4 wherein the body is a container with drug contained therein.
Claim 8
Dependent Claim 14 words
The ocular system according to claim 4 wherein the drug is an ophthalmic drug.
Claim 9
Dependent Claim 12 words
The ocular system according to claim 4 wherein the drug is pilocarpine.
Claim 10
Dependent Claim 145 words
An ocular therapeutic system for the controlled and continuous administration of drug to the eye of a warm blooded animal comprising a body formed of a polymeric material permeable to the passage of drug by diffusion and surrounding a drug capable of diffusing through the material at a therapeutically effective rate, the body shaped, adapted and sized with a length of 4 to 20 mm, a width of 0.1 to 12 mm and a thickness of 0.1 to 4 mm for insertion and retention in the eye, and wherein the material comprises an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight and melt index of about 0.1 to 1000 grams per ten minutes, with the copolymer when the system is in the eye administering drug to the eye at a controlled rate over a prolonged period of time.
Claim 11
Dependent Claim 145 words
An ocular therapeutic system for the controlled and continuous administration of drug to the eye of a warm blooded animal comprising a body formed of a polymeric material permeable to the passage of drug by diffusion and surrounding a drug capable of diffusing through the material at a therapeutically effective rate, the body shaped, adapted and sized with a length of 4 to 20 mm, a width of 0.1 to 12 mm and a thickness of 0.1 to 4 mm for insertion and retention in the eye, and wherein the material comprises an ethylene-vinyl acetate copolymer having a vinyl acetate content of about 4 to 80% by weight and melt index of about 0.1 to 1000 grams per ten minutes, with the copolymer when the system is in the eye administering drug to the eye at a controlled rate over a prolonged period of time.
Claim 12
Dependent Claim 19 words
The ocular system according to claim 8 wherein the body is a container and the drug is contained therein.
Claim 13
Dependent Claim 17 words
The ocular system according to claim 8 wherein the copolymer surrounds a reservoir containing an ophthalmic drug.
Claim 14
Dependent Claim 12 words
The ocular system according to claim 8 wherein the drug is pilocarpine.
Claim 15
Dependent Claim 97 words
An ocular therapeutic system for the controlled administration of drug to the eye comprising a body formed of a drug release rate controlling ethylene-vinyl acetate copolymer permeable to the passage of drug by diffusion and containing a dosage amount of a drug capable of diffusing through the copolymer, said body shaped, adapted and sized for comfortable insertion and placement in the eye, and wherein the body when in the eye administers a therapeutically effective amount of drug by the drug dissolving in and passing through the copolymer at a controlled rate over a prolonged period of time.
Claim 16
Dependent Claim 97 words
An ocular therapeutic system for the controlled administration of drug to the eye comprising a body formed of a drug release rate controlling ethylene-vinyl acetate copolymer permeable to the passage of drug by diffusion and containing a dosage amount of a drug capable of diffusing through the copolymer, said body shaped, adapted and sized for comfortable insertion and placement in the eye, and wherein the body when in the eye administers a therapeutically effective amount of drug by the drug dissolving in and passing through the copolymer at a controlled rate over a prolonged period of time.
Claim 17
Dependent Claim 52 words
The ocular system according to claim 12 wherein the copolymer has a vinyl acetate content of 4 to 50% by weight, a melt index of 0.5 to 250 grams per 10 minutes, a density of 0.920 to 0.980, and a frequency of acetoxy groups on the ethylene backbone of 1/150 to 1/8.
Claim 18
Dependent Claim 14 words
The ocular system according to claim 12 wherein the drug is an ophthalmic drug.
Claim 19
Dependent Claim 12 words
The ocular system according to claim 12 wherein the drug is pilocarpine.
Claim 20
Dependent Claim 93 words
An ocular therapeutic system for administering drug to the eye comprising a body shaped and sized for comfortable insertion and retention in the eye, the body formed of a drug release rate controlling ethylene-vinyl acetate copolymer having a vinyl acetate content of 4 to 80% by weight, permeable to the passage of drug by diffusion and surrounding a drug capable of diffusing therethrough, and wherein said body when in the eye administers a therapeutically effective amount of drug by passage through the copolymer at a controlled rate over a prolonged period of time.
Claim 21
Dependent Claim 93 words
An ocular therapeutic system for administering drug to the eye comprising a body shaped and sized for comfortable insertion and retention in the eye, the body formed of a drug release rate controlling ethylene-vinyl acetate copolymer having a vinyl acetate content of 4 to 80% by weight, permeable to the passage of drug by diffusion and surrounding a drug capable of diffusing therethrough, and wherein said body when in the eye administers a therapeutically effective amount of drug by passage through the copolymer at a controlled rate over a prolonged period of time.
Claim 22
Dependent Claim 35 words
The ocular system for administering drug to the eye according to claim 16 wherein the copolymer has a melt index of 0.1 to 1000 grams per 10 minutes and the drug is an ophthalmic drug.
Claim 23
Dependent Claim 21 words
The ocular system according to claim 16 wherein the body is a container with the drug contained in the reservoir thereof.
Claim 24
Dependent Claim 12 words
The ocular system according to claim 16 wherein the drug is pilocarpine.

References Cited (Backward Citations)

US3854480A Cited
US3710795A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-10-03 1981-04-04 1981-10-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-10-03 1985-04-04 1985-10-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-10-03 1989-04-04 1989-10-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag